Interleukin (IL)-21-independent pathogen-specific CD8+ T-cell expansion, and IL-21-dependent suppression of CD4+ T-cell IL-17 production.
Although interleukin-21 (IL-21) potently activates and controls the differentiation of immune cells after stimulation in vitro, the role for this pleiotropic cytokine during in vivo infection remains poorly defined. Herein, the requirement for IL-21 in innate and adaptive host defence after Listeria monocytogenes infection was examined. In the innate phase, IL-21 deficiency did not cause significant defects in infection susceptibility, or in the early activation of natural killer and T cells. In the adaptive phase, L. monocytogenes-specific CD8(+) T cells expand to a similar magnitude in IL-21-deficient mice compared with control mice. Interestingly, the IL-21-independent expansion of L. monocytogenes-specific CD8(+) T cells was maintained even in the combined absence of IL-12 and type I interferon (IFN) receptor. Similarly, L. monocytogenes-specific CD4(+) T cells expanded and produced similar levels of IFN-γ regardless of IL-21 deficiency. Unexpectedly however, IL-21 deficiency caused significantly increased CD4(+) T-cell IL-17 production, and this effect became even more pronounced after L. monocytogenes infection in mice with combined defects in both IL-12 and type I IFN receptor that develop a T helper type 17-dominated CD4(+) T-cell response. Despite increased CD4(+) T-cell IL-17 production, L. monocytogenes-specific T cells re-expanded and conferred protection against secondary challenge with virulent L. monocytogenes regardless of IL-21 deficiency, or combined defects in IL-21, IL-12, and type I IFN receptor. Together, these results demonstrate non-essential individual and combined roles for IL-21, IL-12 and type I IFNs in priming pathogen-specific CD8(+) T cells, and reveal IL-21-dependent suppression of IL-17 production by CD4(+) T cells during in vivo infection.
Ertelt
James M
JM
Department of Pediatrics, Center for Infectious Disease and Microbiology Translational Research, School of Medicine, University of Minnesota, Minneapolis, MN, USA.
Johanns
Tanner M
TM
Rowe
Jared H
JH
Way
Sing Sing
SS
D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology / Q000276:immunology* / Q000378:metabolism; D018414:CD8-Positive T-Lymphocytes / Q000166:cytology / Q000276:immunology*; D002454:Cell Differentiation / Q000235:genetics / Q000276:immunology; D007109:Immunity / Q000235:genetics / Q000276:immunology; D007113:Immunity, Innate / Q000235:genetics / Q000276:immunology; D007371:Interferon-gamma / Q000097:blood / Q000378:metabolism; D018664:Interleukin-12 / Q000235:genetics; D020381:Interleukin-17 / Q000096:biosynthesis*; D007378:Interleukins / Q000235:genetics / Q000276:immunology*; D007694:Killer Cells, Natural / Q000378:metabolism; D008089:Listeria monocytogenes / Q000235:genetics / Q000276:immunology*; D008088:Listeriosis / Q000276:immunology / Q000378:metabolism / Q000382:microbiology / Q000401:mortality; D008099:Liver / Q000382:microbiology; D008213:Lymphocyte Activation / Q000235:genetics / Q000276:immunology*; D018655:Lymphocyte Count; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D053633:Receptor, Interferon alpha-beta / Q000235:genetics; D013154:Spleen / Q000382:microbiology; D000098546:Interleukin-21
D020381:Interleukin-17; D007378:Interleukins; D053633:Receptor, Interferon alpha-beta; D018664:Interleukin-12; D007371:Interferon-gamma; D000098546:Interleukin-21
J Immunol. 2008 Jun 1;180(11):7097-101
18490706
J Exp Med. 2004 Aug 16;200(4):527-33
15302899
Science. 2009 Jun 19;324(5934):1572-6
19443735
Curr Opin Immunol. 2000 Aug;12(4):425-31
10899025
Science. 2002 Nov 22;298(5598):1630-4
12446913
J Immunol. 2007 Apr 1;178(7):4498-505
17372008
Infect Immun. 1991 Sep;59(9):2892-900
1679040
J Immunol. 2007 Apr 1;178(7):4411-6
17371998
J Exp Med. 2004 Aug 16;200(4):535-40
15302900
Arthritis Rheum. 2007 Apr;56(4):1152-63
17393408
Microbes Infect. 2007 Aug;9(10):1208-15
17719259
J Immunol. 2008 Mar 15;180(6):4109-15
18322221
Eur J Immunol. 2008 Jul;38(7):1833-8
18546146
Proc Natl Acad Sci U S A. 1995 Jan 17;92(2):377-81
7831294
Immunity. 2002 Apr;16(4):559-69
11970879
J Immunol. 2007 Mar 15;178(6):3822-30
17339481
J Immunol. 2007 Aug 15;179(4):2115-25
17675470
J Immunol. 2005 Apr 15;174(8):4465-9
15814665
J Leukoc Biol. 2008 Aug;84(2):348-56
18467657
J Immunol. 2002 Feb 15;168(4):1528-32
11823476
Nat Immunol. 2007 Sep;8(9):967-74
17581537
Science. 2009 Jun 19;324(5934):1569-72
19423777
Science. 2009 Jun 19;324(5934):1576-80
19478140
J Immunol. 2007 Jun 15;178(12):7640-8
17548600
Proc Natl Acad Sci U S A. 2009 Feb 3;106(5):1518-23
19164519
J Exp Med. 2004 Aug 16;200(4):437-45
15302901
J Endotoxin Res. 2006;12(4):246-50
16953977
J Immunol. 2005 May 15;174(10):5936-40
15879085
Nature. 2000 Nov 2;408(6808):57-63
11081504
Int Immunol. 2009 May;21(5):489-98
19261692
Nature. 2007 Jul 26;448(7152):484-487
17581588
J Immunol. 2000 Dec 15;165(12):6833-9
11120806
J Immunol. 1997 Jun 1;158(11):5297-304
9164949
Nat Rev Immunol. 2004 Oct;4(10):812-23
15459672
J Immunol. 2007 Aug 15;179(4):2074-81
17675465
J Immunol. 2008 May 15;180(10):6544-52
18453573
Cytokine Growth Factor Rev. 2007 Jun-Aug;18(3-4):223-32
17509926
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3384-9
17360655
J Exp Med. 2005 Jan 3;201(1):139-48
15630141
Immunity. 1995 Jul;3(1):109-17
7621071
J Exp Med. 2003 Nov 17;198(10):1583-93
14623912
Nature. 2007 Jul 26;448(7152):480-3
17581589
J Immunol. 2004 Feb 15;172(4):2048-58
14764669
J Exp Med. 2005 Apr 4;201(7):1053-9
15809350